Article

3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 72, n° 2
pages 345-348 (février 2015)
Doi : 10.1016/j.jaad.2014.11.002
accepted : 3 November 2014
From the Academy

The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology
 

Alice B. Gottlieb, MD, PhD a, b, Adriane A. Levin, BA a, c, April W. Armstrong, MD, MPH d, April Abernethy, MD e, Kristina Callis Duffin, MD, MS f, Reva Bhushan, MA, PhD g, , Amit Garg, MD h, Joseph F. Merola, MD, MMSc i, Mara Maccarone j, Robin Christensen, MSc, PhD k
a Department of Dermatology, Tufts Medical Center, Boston, Massachusetts 
b Tufts University School of Medicine, Boston, Massachusetts 
c Boston University School of Medicine, Boston, Massachusetts 
d University of Colorado School of Medicine, Denver, Colorado 
e National Psoriasis Foundation, Portland, Oregon 
f Department of Dermatology, University of Utah, Salt Lake City, Utah 
g American Academy of Dermatology, Schaumburg, Illinois 
h Department of Dermatology, Hofstra North Shore Long Island Jewish School of Medicine, Manhasset, New York 
i Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 
j Associazione per la Difesa delgi Proriasici, Rome, Italy 
k Department of Rheumatology, Michigan State University, Parker Institute, Copenhagen, Denmark 

Reprint requests: Reva Bhushan, MA, PhD, American Academy of Dermatology, 930 E Woodfield Road. Schaumburg, IL 60173.
Abstract

As quality standards are increasingly in demand throughout medicine, dermatology needs to establish outcome measures to quantify the effectiveness of treatments and providers. The International Dermatology Outcome Measures Group was established to address this need. Beginning with psoriasis, the group aims to create a tool considerate of patients and providers using the input of all relevant stakeholders in assessment of disease severity and response to treatment. Herein, we delineate the procedures through which consensus is being reached and the future directions of the project.

The full text of this article is available in PDF format.

Key words : body surface area, Delphi exercises, Dermatology Life Quality Index, disease severity, International Dermatology Outcome Measures, National Psoriasis Foundation, Outcome Measures in Rheumatology, patient-centered outcome measures, Physician Global Assessment, psoriasis, Psoriasis Area and Severity Index, psoriatic arthritis, quality of life

Abbreviations used : IDEOM, OMERACT, PASI



 Funding sources: None.
 Disclosure: Dr Gottlieb maintains current consulting/advisory board agreements with Amgen Inc, Astellas, Centocor (Janssen), Celgene Corp, Bristol Meyers Squibb Co, Beiersdorf Inc, Abbott Labs (Abbvie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd, Incyte, Pfizer, Canfite, Eli Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, Glaxo Smith Kline, Xenoport, Catabasis, and Sanofi Aventis. Dr Armstrong served as a consultant and was investigator for Abbvie, Amgen Inc, Janssen, Eli Lilly, Pfizer, and Merck. Dr Abernethy served on the advisory board of Abbvie and as speaker for Pfizer receiving honoraria and is an employee for National Psoriasis Foundation receiving salary. Dr Duffin served on the advisory board and was consultant and investigator for Amgen Inc, Janssen, Eli Lilly, and Pfizer; served as consultant and investigator for VBL Therapeutics receiving honoraria and salary; was investigator for Abbvie receiving salary; and served as consultant for Bristol Myers Squibb Co receiving honoraria. Dr Garg served on the advisory board of Eli Lilly, Amgen Inc, Abbvie, Genentech, and Pfizer receiving honoraria. Dr Merola served on the advisory board and was investigator for Amgen Inc; was on the advisory board on Eli Lilly and Novartis; was an investigator for Pfizer and Biogen; was speaker for Abbvie; and had an “other” relationship with Abbvie and Biogen receiving honoraria. Ms Maccarone is the founder of Associazione per la Difesa degli Psoriasici–Italian Association for Psoriasis receiving no compensation. Dr Christensen receives no compensation from industry. Tufts Medical Center received research/educational grants from Centocor (Janssen), Amgen Inc. Abbott Labs (Abbvie), Novartis, Celgene, Pfizer, Eli Lilly, Coronado, Levia, and Merck. Ms Levin and Dr Bhushan have no conflicts of interest to declare.



© 2014  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline